Grifols reported first-half 2026 results with total revenue of €3,574 million, up 2.6% at constant currency, driven by a 5.4% increase in Biopharma segment sales led by immunoglobulins. Net profit rose 28.7% to €227 million, while adjusted EBITDA reached €854 million with a margin of 23.9%. Free cash flow pre-M&A improved significantly to positive €91 million from negative €12 million in the prior year period. The company successfully refinanced all 2027 debt maturities through an upsized €3 billion Term Loan B and increased revolving credit facility, alongside a €500 million redemption of its 2030 bond, extending its maturity profile with no significant maturities until Q4 2028. Grifols confirmed its full-year 2026 guidance and announced an organizational restructuring to create dedicated U.S. and Rest of World Biopharma entities.

On June 19, 2026, the Board of Directors of Grifols, S.A. acknowledged the resignation of Enriqueta Felip Font from the Board and the Sustainability, Communication and Reputation Committee for professional reasons. The Board appointed Ester Masllorens Llinàs as an independent director via co-option to fill the vacancy. Additionally, Pascal Ravery was appointed to the Sustainability, Communication and Reputation Committee to replace Ms. Felip Font. Grifols, S.A. is a pharmaceutical company specializing in plasma-derived medicines.

At its Ordinary General Shareholders' Meeting on June 18, 2026, Grifols, S.A. approved a mandatory preferred dividend of EUR 0.01 per Class B share and an ordinary dividend totaling EUR 56,065,663, both payable on July 2, 2026. The meeting also approved the re-election of Montserrat Muñoz Abellana and Susana González Rodríguez to the Board of Directors and the re-election of Deloitte Auditores, S.L. as statutory auditor for 2027-2029. Additionally, shareholders authorized the Board to increase share capital by up to 50% over five years, authorized a share capital reduction of up to 10% via treasury share redemption, and approved a new directors' remuneration policy for 2026-2028. One proposal regarding the calling of Extraordinary General Shareholders' Meetings failed to reach a sufficient majority. The company operates in the healthcare industry, specializing in plasma-derived medicines and diagnostics.